Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COT for Cognitive Decline in Early Alzheimer's Disease
NCT05122598Phase 2Unknown
- Sponsor
- Evon Medics
- Start
- Nov 2021
- Primary completion
- Apr 2023
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Computerized Olfactory Training in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Evon Medics. Primary endpoints: Logical Memory II subscale (Delayed Paragraph Recall) at 9 months, Alzheimer's Disease Cooperative Study-Preclinical Alzheimer Cognitive Composite at 9 months and 3 more. Status: unknown.
02
Drugs
Computerized Olfactory Training
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05122598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122598.